CETP and metabolic syndrome: Although Liao et al19 dedicate the effect of ONX-0914 to increased efferocytosis upon immunoproteasomal inhibition, we find numerous additional beneficial immune effects of ONX-0914 treatment in the context of initial and advanced atherosclerosis in LDLr–/– mice, as well as substantial improvements in markers of metabolic syndrome in LDLr–/– and E3L.CETP mice.